Table 2.
Treatment with other dopaminergic Parkinson’s disease (PD) medication prior to LC-5 and concomitant PD treatment during LC-5 therapy (n = 29).
| PD Medication | Number of Patients, Prior to LC-5 | Number of Patients, during LC-5 |
|---|---|---|
| Levodopa/decarboxylase inhibitor | 22 | 12 |
| Entacapone; Levodopa/carbidopa/entacapone | 6 | 4 |
| Amantadine | 3 | 0 |
| Dopamine agonist | 23 | 18 |
| MAO-B-I | 14 | 14 |
| Median daily dose of L-DOPA (mg) | 600 | 690 |
| Median LED (mg) | 878 | 910 |
One patient was not treated with levodopa prior to LC-5 due to severe neurogenic orthostatic hypotension, which worsened with previous attempts using standard levodopa formulations. LC-5: levodopa-carbidopa microtablets; LED: levodopa-equivalent daily dose; MAO-B-I: monoamine oxidase B inhibitor.